Effect of esketamine combined with sufentanil on patient controlled intravenous analgesia after surgery for developmental dysplasia of the hip in children

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300073016

Enrollment

Unknown

Registered

2023-06-29

Start date

2023-07-01

Completion date

Unknown

Last updated

2023-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

developmental dysplasia of the hip

Interventions

GROUP K:Esketamine combined with sufentanil for postoperative analgesia

GROUP K:Sufentanil for postoperative analgesia

Eligibility

Sex/Gender

All

Age

1.5 Years to 12 Years

Inclusion criteria

Inclusion criteria: (1) ASA I-II level; (2) Children undergoing DDH surgery; (3) Willingness to use patient-controlled intravenous analgesia (PCIA).

Exclusion criteria

Exclusion criteria: (1) ASAIII level and above; (2) Emergency surgery or trauma patients; (3) There are contraindications for nerve block, such as prolonged coagulation time and infection at the puncture site; (4) History of allergy to narcotic drugs, ropivacaine or esketamine; (5) Mental illness and chronic pain that may confuse analgesic effects; (6) Have a medical history known during the operation; (7) Postoperative transfer to ICU; (8) Unwilling to use PCIA or refuse to participate in this study.

Design outcomes

Primary

Measure	Time frame
pain score;	—

Secondary

Measure	Time frame
PCIA Press Times;Total amount of rescue Analgesic;hospital stay;	—

Countries

CHINA

Contacts

Public ContactHuang Jinjin

Children's Hospital of Zhejiang University School of Medicine

6196008@zju.edu.cn+86 136 0652 2815

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026